Roche, obesity and Zealand Pharma

No. 4 / 2025Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.